Personalized medicine and access to health care: Potential for inequitable access?

European Journal of Human Genetics

Volumn 21, Issue 2, 2013, Pages 143-147

  McClellan, Kelly A ^a   Avard, Denise ^a   Simard, Jacques ^b   Knoppers, Bartha M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Université Laval   (Canada)

Author keywords

breast cancer; equitable access; Genetic testing; personalized medicine; risk assessment

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; GENETIC RISK; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH INSURANCE; HEREDITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

BREAST NEOPLASMS; DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84872489789     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.149     Document Type: Article

References (72)

1. Hamburg MA, Collins FS: The path to personalized medicine. N Engl J Med 2010; 363: 301-304.
2. Chan IS, Ginsburg GS: Personalized medicine: progress and promise. Ann Rev Genomics Human Genet 2011; 12: 217-244.
3. Aspinall MG, Hamermesh RG: Realizingthe Promise of personalized medicine. Harvard Business Rev2007; 85: 108.
4. Billings PR, Kohn MA, deCuevas M, Beckwith J, Alper JS, Natowicz MR: Discrimina-tion as a consequence of genetic testing. Am J Hum Genet 1992; 50: 476-482.
5. Hudson KL: Prohibiting genetic discrimination. N Engl J Med 2007; 356: 2021-2023.
6. Zukerman W: Genetic discrimination in the workplace: towards legal certainty in uncertain times. J Law Med 2009; 16: 770-788.
7. Rothstein MA: Currents in contemporary ethics. GINA, the ADA, and genetic discrimination in employment. J Law Med Ethics 2008; 36: 837-840.
8. Joly Y, Braker M, Le Huynh M: Genetic discrimination in private insurance: global perspectives. New Genet Soc 2010; 29: 351-368.
9. Quillian L: New approaches to understanding racial prejudice and discrimination. Ann Rev Sociol 2006; 32: 299-328.
10. Wright CF, Burton H, Hall A et al. Next Steps in the Sequence: The Implications of Whole Genome Sequencing for Health in the UK. Cambridge: PHG Foundation, 2011.
11. Burke W, Burton H, Hall AE etal: Extendingthe reach of public health genomics: what should be the agenda for public health in an era of genome-based and 'personalized' medicine? Genet Med 2010; 12: 785-791.
12. Green ED, Guyer MS: Charting a course for genomic medicine from base pairs to bedside. Nature 2011; 470: 204-213.
13. Borden EC, Raghavan D: Personalizing medicine for cancer: the next decade. Nat Rev Drug Discov 2010; 9: 343-344.
14. Schilsky RL: Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010; 9: 363-366.
15. Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K: Genetics, genomics, and cancer risk assessment. CA Cancer J Clin 2011; 61: 327-359.
16. Khoury MJ, Feero WG, Valdez R: Family history and personal genomics as tools for improving health in an era of evidence-based medicine. Am J Prev Med 2010; 39: 184-188.
17. Amir E, Freedman OC, Seruga B, Evans DG: Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst2010; 102: 680-691.
18. MacInnis RJ, Antoniou AC, Eeles RA etal: A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol 2011; 35: 549-556.
19. Kratz CP, Greene MH, Bratslavsky G, Shi J: A stratified genetic risk assessment for testicular cancer. Int J Androl2011; 34: e98-e102.
20. Raji OY, Agbaje OF, Duffy SW, Cassidy A, Field JK: Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: the Liverpool Lung Project. Cancer Prevent Res 2010; 3: 664-669.
21. Jostins L, Barrett JC: Genetic risk prediction in complex disease. Hum Mol Genet 2011; 20: R182-R188.
22. Ashley EA, Butte AJ, Wheeler MT et al. Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525-1535.
23. Evans GR, Lalloo F: Development of a scoring system to screen for BRCA1/2 mutations. Methods Mol Biol 2010; 653: 237.
24. Montori VM, Guyatt GH: Progress in evidence-based medicine. JAMA 2008; 300: 1814-1816.
25. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-72.
26. Evidence-based medicine. A newapproach to teachingthe practiceof medicine. JAMA 1992; 268: 2420-2425.
27. Beauchamp TL, Childress JF: Principles of Biomedical Ethics. USA: Oxford University Press, 2001.
28. Goering S, Holland S, Edwards K: Making good on the promise of genetics: justice in translational science. Achieving Justice in Genomic Translation: Re-Thinking the Pathway to Benefit New York, NY, USA: Oxford University Press, 2011, pp 1-21.
29. Rogowski WH, Grosse SD, Khoury MJ: Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 2009; 10: 489-495.
30. Kurian AW, Gong GD, John EM et al. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2009; 18: 1084-1091.
31. Jacobi C, de Bock G, Siegerink B, van Asperen C: Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 2009; 115: 381-390.
32. Antoniou AC, Hardy R, Walker L et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008; 45: 425-431.
33. Pankratz VS, Hartmann LC, Degnim AC et al. Assessment of the accuracy of the gail model in women with atypical hyperplasia. J Clin Oncol 2008; 26: 5374-5379.
34. Mackarem G, Roche CA, Hughes KS: The effectiveness of the gail model in estimating risk for development of breast cancer in women under 40 years of age. Breast J 2001; 7: 34-39.
35. Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH: Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the florence-european prospective investigation into cancer and nutrition cohort. J Natl Cancer Inst 2006; 98: 1686-1693.
36. Antoniou AC, Durocher F, Smith P, Simard J, Easton DF: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 2006; 8: R3.
37. Banegas MP, Gail MH, Lacroix A et al. Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat2011; 132: 347-353.
38. Ulusoy C, Kepenekci I, Kose K, Ayd?ntugS, Cam R: Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor. Breast Cancer Res Treat 2010; 120: 419-424.
39. Adams-Campbell LL, Makambi KH, FrederickWA, Gaskins M, Dewitty RL, McCaskill-Stevens W: Breast cancer risk assessments comparing Gail and CARE models in African-American women. Breast J 2009; 15:Suppl 1 S72-S75.
40. Shojamoradi MH, Majidzadeh-A K, Najafi M, Najafi S, Abdoli N: Breast cancer risk assessment byGail model in Iranian patients: accuracy and limitations. Eur J Cancer Suppl 2008; 6: 74-74.
41. Kurian AW: BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. CurrOpin Obstet Gynecol 2010; 22: 72-78.
42. Meads C, Ahmed I, Riley RD: A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat 2011; 132: 365-377.
43. Roudgari H, Miedzybrodzka ZH, Haites NE: Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models. Fam Cancer 2008; 7: 199-212.
44. Santen RJ, Boyd NF, Chlebowski RT et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007; 14: 169-187.
45. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V, Thakkinstian A: Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat 2011; 133: 1-10.
46. Valdez R, Yoon PW, Qureshi N, Green RF, Khoury MJ: Family history in public health practice: a genomictool for disease prevention and health promotion&z.ast;. Ann RevPublic Health 2010; 31: 69-87.
47. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21: 2397-2406.
48. Plat AW, Kroon AA, Van Schayck CP, De Leeuw PW, Stoffers HE: Obtaining the family history for common, multifactorial diseases by family physicians. A descriptive systematic review. Eur J Gen Pract 2009; 15: 231-242.
49. BergAO, Baird MA, Botkin JR etal: National Institutesof Health State-of-the-Science Conference Statement: Family History and Improving Health: August 24-26, 2009. NIH Consens State Sci Statements 2009; 26: 1-19.
50. Qureshi N, Carroll JC, Wilson B et al. The current state of cancer family history collection tools in primary care: a systematic review. Genet Med2009; 11: 495-506.
51. Kelly KM, Sturm AC, Kemp K, Holland J, Ferketich AK: How can we reach them? Information seeking and preferences for a cancer family history campaign in under-served communities. J Health Commun 2009; 14: 573-589.
52. Petruccio C, MillsShawKR, Boughman J etal: Healthy choices through family history: a communityapproachto family history awareness. Comm Genet 2008; 11: 343-351.
53. Murff HJ, Byrne D, Haas JS, Puopolo AL, Brennan TA: Race and family history assessment for breast cancer. J Gen Intern Med 2005; 20: 75-80.
54. Murff HJ, Peterson NB, Greevy R, Zheng W: Impact of patient age on family cancer history. Genet Med 2006; 8: 438.
55. Murff HJ, Spigel DR, Syngal S: Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004; 292: 1480-1489.
56. Abraham L, Geller BM, Yankaskas BC et al. Accuracy of self-reported breast cancer amongwomen undergoing mammography. Breast Cancer Res Treatment 2009; 118: 583-592.
57. Dominguez FJ, Lawrence C, Halpern EF et al. Accuracy of self-reported personal historyof cancer in an outpatient breast center. J Genet Counsel 2007; 16: 341-345.
58. Soegaard M, Jensen A, Frederiksen K et al. Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. Cancer Causes Control 2008; 19: 469-479.
59. Nycum G, Avard D, Knoppers B: Intra-familial obligationsto communicate genetic risk information: What foundations? What forms? McGill J Law Health 2009; 3: 21-48.
60. Maradiegue A, Edwards QT: An overview of ethnicity and assessment of family history in primary care settings. J Am Acad Nurse Pract 2006; 18: 447-456.
61. United Nations: International Covenant on Economic, Social and Cultural Rights; in: Nations U (ed), 3 January 1976.
62. de Groot R: Right to health care and scarcity of resources; in Gevers J, Hondius EH, Hubben J (eds): Health Law, Human Rights and the Biomedicine Convention: Essays in Honour of Henriette Roscam Abbing. Leiden, The Netherlands: Martinus Nijhoff Publishers, 2005; Vol 85, pp 49-59.
63. Flood CM: Just Medicare: What's In, What's Out, How We Decide. Toronto, Ontario, Canada: University of Toronto Press, 2006.
64. Burke W, Press N: What outcomes? Whose benefits? in Burke W, Edwards K, Goering S, Holland S, Trinidad SB (eds): Achieving Justice in Genomic Translation: Re-Thinking the Pathway to Benefit New York, NY, USA: Oxford University Press, 2011, p 162.
65. Bustamante CD, De La Vega FM, Burchard EG: Genomics for the world. Nature 2011; 475: 163-165.
66. Potter BK, Avard D, Graham ID et al. Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening. Int J Technol Assess Health Care 2008; 24: 412-422.
67. Landry R, Amara N, Pablos-Mendes A, Shademani R, Gold I: The knowledge-value chain: a conceptual framework for knowledge translation in health. Bull World Health Organization 2006; 84: 597-602.
68. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L: The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9: 665-674.
69. Droste S, Dintsios CM, Gerber A: Information on ethical issues in health technology assessment: howand where tofind them. Int J Technol Assess Health Care 2010; 26: 441-449.
70. Gudgeon JM, McClain MR, Palomaki GE, Williams MS, Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing. Genet Med 2007; 9: 473-478.
71. Sanderson S, Zimmern R, Kroese M, Higgins J, Patch C, Emery J: How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med 2005; 7: 495-500.
72. Potter BK, Avard D, Entwistle V et al. Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report. Public Health Genomics 2008; 12: 4-10.